<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703910</url>
  </required_header>
  <id_info>
    <org_study_id>CNIO-GI-01-2012</org_study_id>
    <nct_id>NCT01703910</nct_id>
  </id_info>
  <brief_title>Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic</brief_title>
  <official_title>Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Nacional de Investigaciones Oncologicas CARLOS III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario de Fuenlabrada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Hospital de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Nacional de Investigaciones Oncologicas CARLOS III</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility of selecting personalized therapies&#xD;
      for colon cancer patients who have failed standard treatments, using a new methodology based&#xD;
      on the determination of a profile of chemosensitivity by comprehensive genetic expression&#xD;
      analysis from tumor samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective, randomized study in patients with metastatic colorectal carcinoma&#xD;
      progressing after two lines of prior therapy. Patients will be randomized (1:1) to receive&#xD;
      chemotherapy as determined by its oncologist or treatment according to chemosensitivity&#xD;
      profile obtained. For obtaining the profile a histological tumor sample and a sample of&#xD;
      venous blood in a tube with heparin standard are necessary . This latter sample will be&#xD;
      processed to isolate circulating tumor cells by cell adhesion with matrix coated glass&#xD;
      spheres. The RNA from these circulating tumor cells as well as from tumor cells of tumor&#xD;
      biopsies from the same patients will be extracted by a standard procedure for extracting RNA&#xD;
      for genetic expression analysis. Based on the analysis performed on tumor biopsy is generated&#xD;
      a ranked list of potentially more effective treatments in every case&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the tumor progression-free survival at 3 and 6 months (PFS3 and PFS6) in both groups of patients and identify whether there is a statistically significant difference</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gene expression profiles</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the correlation between the gene expression profiles obtained from the CTC and the gene expression profiles obtained from tumor samples from the same patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Adenocarcinoma of Colon</condition>
  <condition>Adenocarcinoma of Rectum</condition>
  <condition>Metastatic Disease</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment guided by the gene expression profiles obtained from the CTC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A chemotherapy</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Capecitabine</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>Cetuximab</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Fluorouracil</other_name>
    <other_name>Gemcitabine</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>Topotecan</other_name>
    <other_name>Mitomycin C</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Paclitaxel</other_name>
    <other_name>Docetaxel</other_name>
    <other_name>Pemetrexed</other_name>
    <other_name>Raltitrexed</other_name>
    <other_name>Sorafenib</other_name>
    <other_name>Erlotinib</other_name>
    <other_name>Vinorelbine</other_name>
    <other_name>Dasatinib</other_name>
    <other_name>Etoposide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arm B chemotherapy</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Capecitabine</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>Cetuximab</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Fluorouracil</other_name>
    <other_name>Gemcitabine</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>Topotecan</other_name>
    <other_name>Mitomycin C</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Paclitaxel</other_name>
    <other_name>Docetaxel</other_name>
    <other_name>Pemetrexed</other_name>
    <other_name>Raltitrexed</other_name>
    <other_name>Sorafenib</other_name>
    <other_name>Erlotinib</other_name>
    <other_name>Vinorelbine</other_name>
    <other_name>Dasatinib</other_name>
    <other_name>Etoposide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological examination showed of metastatic colon carcinoma.&#xD;
&#xD;
          -  Patients more than 18 years.&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 criteriso&#xD;
&#xD;
          -  Life expectancymore than 3 months according to the criteria of the investigator.&#xD;
&#xD;
          -  Goodoverall condition determined by the ECOG scale (score 0-1)&#xD;
&#xD;
          -  Candidate for systemic treatment based on the profile of sensibility to drugs&#xD;
             determined by genetic analysis of the tumor sample. Patients should have received at&#xD;
             least two lines of standard treatment, including therapies antiEGFR in cases of tumors&#xD;
             with Kras oncogene B-Raf and native (non-mutated).&#xD;
&#xD;
          -  Availability of tumor tissue or potential for tumor biopsy correlation allowing the&#xD;
             RNA expression profile with that obtained from the peripheral blood CTCs.&#xD;
&#xD;
          -  Adequate hematologic function: ANCmore than 1.5 x 103 / L, platelet count absolute&#xD;
             more than 100 x 109 / L, normal values of INR and PTT.&#xD;
&#xD;
          -  Adequate liver function: total serum bilirubin no more than 2 mg / dL, ALT and AST no&#xD;
             more than 3 times the upper limit established by the laboratory (LSR) or no more than&#xD;
             5 LSR in patients with liver metastases.&#xD;
&#xD;
          -  Adequate renal function: serum creatinine no more than 1.5 LSR or calculated&#xD;
             creatinine clearance 60 ml / min (Crock).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has received systemic cancer treatment within two weeks prior to&#xD;
             extraction of the blood sample.&#xD;
&#xD;
          -  Patient has received therapeutic radioisotopes such as strontium 89 within 4 weeks&#xD;
             before blood extraction.&#xD;
&#xD;
          -  Patient has had major surgery or percutaneous procedures such as placement of central&#xD;
             venous catheter within 2 weeks prior to the blood draw.&#xD;
&#xD;
          -  Patient has a history as bone marrow transplantation and / or stem cell&#xD;
             transplantation.&#xD;
&#xD;
          -  Patient has any of the following concomitant diseases or current conditions:&#xD;
&#xD;
        chronic active liver disease of any origin, and / or cirrhosis with Child-Pugh score B or&#xD;
        C.&#xD;
&#xD;
        Uncontrolled active infection. carries the human immunodeficiency virus (HIV). Any other&#xD;
        significant disease that in the opinion of the investigator, substantially increase the&#xD;
        risk associated with patient participation in this study.&#xD;
&#xD;
        documented symptomatic brain metastases, progression or requiring corticosteroids or&#xD;
        associated to a leptomeningeal involvement.&#xD;
&#xD;
        Patients with uncontrolled systemic diseases. Patients with Hypertension or Diabetes&#xD;
        Mellitus is countable if at the time of inclusion deemed medically controlled.&#xD;
&#xD;
        Patients with inability for oral drug delivery, either by preventing gastrointestinal&#xD;
        administration situation or severe impairment of intestinal absorption&#xD;
&#xD;
          -  Any medical or psychiatric condition that, in the opinion of the investigator, may&#xD;
             limit the patient's ability to understand and fulfill all requirements under its&#xD;
             partcipación in the study.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Gómez, M.D.,Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Centro Nacional de Investigaciones Oncológicas (CNIO)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 8, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genomic expression profile in tumor samples</keyword>
  <keyword>Adult patients</keyword>
  <keyword>metastatic disease status and progression after two lines of systemic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

